1
|
Couderc AL, Nouguerède E, Baumstarck K, Loubière S, Le Caer H, Guillem O, Rousseau F, Greillier L, Norguet-Monnereau E, Cecile M, Boulahssass R, Le Caer F, Tournier S, Butaud C, Guillet P, Nahon S, Kirscher S, Diaz N, Morando C, Villani P, Auquier P, Daumas A. PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: update to the study protocol for a randomized controlled trial. Trials 2019; 20:54. [PMID: 30646923 PMCID: PMC6334455 DOI: 10.1186/s13063-018-3127-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Accepted: 12/11/2018] [Indexed: 11/10/2022] Open
Abstract
Background Social isolation potentiates the risk of death by cancer in the older cancer patient population. The PREDOMOS study investigates the impact of establishing a Program of Social intervention associated with techniques of Domotic and Remote assistance on the improvement of quality of life of older isolated patients, treated for locally advanced or metastatic cancer. This paper updates the pilot trial protocol. Methods/design The original protocol was published in Trials, accessible at https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-1894-7. This update reports on the eligibility criteria expansion and on the adjunction of a cost-utility analysis. We widened the eligible population to patients with locally advanced or metastatic cancer including malignant hemopathies (except acute myeloid leukemia) and to patients in the first and second lines of oncologic treatment. We restricted the inclusion to patients with a Mini Mental State Examination score strictly over 24. In addition to the secondary outcomes outlined in the protocol, a medico-economic analysis has been added to evaluate both the health benefits and costs of the two strategies and calculate the incremental cost-utility ratio of the innovative program assessed, compared to the standard practice. Trial registration ClinicalTrials.gov, NCT02829762. Registered on 29 June 2016.
Collapse
Affiliation(s)
- Anne-Laure Couderc
- Service de Médecine Interne Gériatrie et Thérapeutique, CHU Sainte Marguerite, Assistance Publique des Hôpitaux de Marseille (AP-HM), 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille, cedex 09, France.,Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France
| | - Emilie Nouguerède
- Service de Médecine Interne Gériatrie et Thérapeutique, CHU Sainte Marguerite, Assistance Publique des Hôpitaux de Marseille (AP-HM), 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille, cedex 09, France. .,Service d'Oncologie Digestive, CHU Timone, AP-HM, 264 Rue Saint Pierre, 13385, Marseille, cedex 05, France.
| | - Karine Baumstarck
- EA3279, Self-perceived Health Assessment Research Unit, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, cedex 05, France
| | - Sandrine Loubière
- EA3279, Self-perceived Health Assessment Research Unit, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, cedex 05, France
| | - Hervé Le Caer
- Service de Pneumologie, CH Yves le Foll, 10 rue Marcel Proust, Saint-Brieuc, France
| | - Olivier Guillem
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Onco-Gériatrie, CH Intercommunal des Alpes du Sud Site de Gap (CHICAS), 1 Place Auguste Muret, 05000, Gap, France
| | - Frédérique Rousseau
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Oncologie Médicale, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite Dromel, 13009, Marseille, France
| | - Laurent Greillier
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Oncologie Multidisciplinaire et Innovation Thérapeutique, CHU NORD, AP-HM, Chemin des Bourrely, 13915, Marseille, cedex 20, France
| | - Emmanuelle Norguet-Monnereau
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Oncologie Digestive, CHU Timone, AP-HM, 264 Rue Saint Pierre, 13385, Marseille, cedex 05, France
| | - Maud Cecile
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Oncologie Médicale, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite Dromel, 13009, Marseille, France
| | - Rabia Boulahssass
- Service de Gérontologie, Hôpital de Cimiez, 4 Avenue Reine Victoria, CS 91179, 06003, Nice, France
| | - Françoise Le Caer
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service de Gériatrie, CH Yves le Foll, 10 rue Marcel Proust, Saint-Brieuc, France
| | - Sandrine Tournier
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service de Gériatrie, Hôpital Saint Joseph, 26 Boulevard Louvain, 13285, Marseille, cedex 08, France
| | - Chantal Butaud
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Unité Mobile de Gériatrie, Hôpital Saint Musse, CH Intercommunal Toulon-La Seyne sur Mer (CHITS), 54 Rue Henri Claire Deville, 83000, Toulon, France
| | - Pierre Guillet
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Unité Mobile de Gériatrie, Hôpital Saint Musse, CH Intercommunal Toulon-La Seyne sur Mer (CHITS), 54 Rue Henri Claire Deville, 83000, Toulon, France
| | - Sophie Nahon
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Hémato-Oncologie, CH du Pays d'Aix, Avenue les Tamaris, 13616, Aix-en-Provence, France
| | - Sylvie Kirscher
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Oncologie Médicale, Institut Sainte Catherine (ISC), 250 Chemin de Baigne Pieds, 84918, Avignon, cedex 09, France
| | - Nadine Diaz
- Service Social, Hôpital Sainte Marguerite, AP-HM, 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille, cedex 09, France
| | - Claire Morando
- Direction de la Recherche Clinique et de l'Innovation (DRCI), AP-HM, 80 Rue Brochier, 13354, Marseille, cedex 05, France
| | - Patrick Villani
- Service de Médecine Interne Gériatrie et Thérapeutique, CHU Sainte Marguerite, Assistance Publique des Hôpitaux de Marseille (AP-HM), 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille, cedex 09, France
| | - Pascal Auquier
- EA3279, Self-perceived Health Assessment Research Unit, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, cedex 05, France
| | - Aurélie Daumas
- Service de Médecine Interne Gériatrie et Thérapeutique, CHU Sainte Marguerite, Assistance Publique des Hôpitaux de Marseille (AP-HM), 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille, cedex 09, France
| |
Collapse
|
2
|
Rousseau MC, Baumstarck K, Leroy T, Khaldi-Cherif C, Brisse C, Boyer L, Resseguier N, Morando C, Billette De Villemeur T, Auquier P. Impact of caring for patients with severe and complex disabilities on health care workers' quality of life: determinants and specificities. Dev Med Child Neurol 2017; 59:732-737. [PMID: 28432687 DOI: 10.1111/dmcn.13428] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/15/2017] [Indexed: 11/30/2022]
Abstract
AIM Individuals with severe and complex disabilities, defined by a combination of profound intellectual impairment and serious motor deficit resulting in extreme dependence, often remain in hospital or at residential facilities. The aim of this study was to identify the determinants of quality of life (QoL) of 238 health care workers (HCWs) caring for individuals with severe and complex disabilities. METHOD We conducted a cross-sectional study. The recruitment of the HCWs was performed in five French centres specializing in patients with severe and complex disabilities. The selection criteria were age above 18 years, being an institutional referent HCW (a resource person coordinating various issues for or about the patient), and agreeing to participate. Sociodemographic, health, professional variables, and psycho-behavioural (QoL, burn-out, and coping strategies) data were collected. RESULTS Of the 362 eligible HCWs, 65.7% returned the questionnaires. The scores of the physical and social dimensions of QoL were significantly lower, and the score of the psychological dimension significantly higher, than those of a comparison group. The main factors modulating QoL were age, financial difficulties, nature of coping strategy, and burn-out. INTERPRETATION This research provides preliminary evidence that caring for patients with severe and complex disabilities affects the QoL of HCWs. These results support the need for optimization of the work environments for HCWs.
Collapse
Affiliation(s)
- Marie-Christine Rousseau
- Fédération des Hôpitaux de Polyhandicap et Multihandicap Hôpital San Salvadour, Assistance Publique Hôpitaux de Paris, Hyères, France.,Self-Perceived Health Assessment Research Unit, School of Medicine, Aix Marseille Université, Marseille, France
| | - Karine Baumstarck
- Self-Perceived Health Assessment Research Unit, School of Medicine, Aix Marseille Université, Marseille, France
| | - Tanguy Leroy
- Groupe de Recherche de Psychologie Sociale (GRePS), Université Lyon 2, Lyon, France
| | | | - Catherine Brisse
- Comité d'Études, d'Éducation et de Soins Auprès des Personnes Polyhandicapées, Paris, France
| | - Laurent Boyer
- Self-Perceived Health Assessment Research Unit, School of Medicine, Aix Marseille Université, Marseille, France
| | - Noémie Resseguier
- Self-Perceived Health Assessment Research Unit, School of Medicine, Aix Marseille Université, Marseille, France
| | - Claire Morando
- Self-Perceived Health Assessment Research Unit, School of Medicine, Aix Marseille Université, Marseille, France
| | - Thierry Billette De Villemeur
- Service de Neuropédiatrie et Polyhandicap Pédiatrique, Hôpital Trousseau, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Pascal Auquier
- Self-Perceived Health Assessment Research Unit, School of Medicine, Aix Marseille Université, Marseille, France
| |
Collapse
|
3
|
Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJM, Rittmeyer A. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 2014; 25:1044-52. [PMID: 24585722 DOI: 10.1093/annonc/mdu098] [Citation(s) in RCA: 131] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance with or without pemetrexed in nonsquamous nonsmall-cell lung cancer (nsNSCLC). Progression-free survival (PFS) was significantly prolonged with bevacizumab-pemetrexed, but overall survival (OS) data were immature. In this article, we report an independent, updated analysis of survival outcomes in AVAPERL. PATIENTS AND METHODS Patients with advanced nsNSCLC received first-line bevacizumab (7.5 mg/kg), cisplatin (75 mg/m(2)), and pemetrexed (500 mg/m(2)) every 3 weeks (q3w) for four cycles. Nonprogressing patients were randomized to maintenance bevacizumab (7.5 mg/kg) or bevacizumab-pemetrexed (500 mg/m(2)) q3w until progression or consent withdrawal. The primary end point of the trial was PFS; in this independent OS analysis, participating study centers were contacted to collect survival data on patients still alive at the time of the first analysis. RESULTS A total of 376 patients received induction treatment. Disease control was confirmed in 71.9% of patients; 253 patients were randomized to maintenance treatment with bevacizumab (n = 125) or bevacizumab-pemetrexed (n = 128). At a median follow-up of 14.8 months, patients allocated to bevacizumab-pemetrexed had significantly improved PFS versus those on bevacizumab when measured from randomization [7.4 versus 3.7 months, hazard ratio (HR), 0.57, 95% confidence interval (CI) 0.44-0.75); P < 0.0001]. OS events occurred in 58% of all patients. OS was numerically longer with bevacizumab-pemetrexed versus bevacizumab when measured from randomization [17.1 versus 13.2 months, HR 0.87 (0.63-1.21); P = 0.29]. Second-line therapy was administered in 77% and 70% of patients in the bevacizumab and bevacizumab-pemetrexed arms, respectively. No new adverse events were reported during this updated analysis. CONCLUSION In an unselected population of nsNSCLC patients achieving disease control on platinum-based induction therapy, maintenance with bevacizumab-pemetrexed was associated with a nonsignificant increase in OS over bevacizumab alone.
Collapse
Affiliation(s)
- F Barlesi
- Multidisciplinary Oncology and Therapeutic Innovations Department & Centre Investigation Clinique, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, INSERM CIC, Marseille
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Rittmeyer A, Scherpereel A, Gorbunova VA, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts J, Groen HJ, Morando C, Loundou A, Barlesi F. Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.8014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8014 Background: Maintenance monotherapy has been associated with improved survival for NSCLC pts. AVAPERL was designed to evaluate the safety and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatment and demonstrated improved progression-free survival (PFS) (Barlesi, JCO in press). Methods: Pts with advanced nsNSCLC received first-line Bev (7.5 mg/kg), cisplatin (75 mg/m2), and Pem (500 mg/m2) every 3 weeks (q3w) for 4 cycles. Those non progressing were randomized to maintenance Bev (7.5 mg/kg) +/-Pem (500 mg/m2) q3w until progressive disease or unacceptable toxicity. The primary end point (PFS) was met. An independent update analysis has been conducted to assess OS. Results: A total of 376 pts receive induction treatment; 125 and 128 were randomized to the Bev-alone and Bev+Pem arms, respectively. Induction therapy resulted in confirmed disease control in 71.9% of pts. After a median follow-up of 14.8 months, PFS for the Bev+Pem arm was significantly improved both from induction (10.2 v 6.6 m, HR 0.58 [0.45-0.76], p<.0001) and randomization (7.4 v 3.7 m, HR 0.57 [0.44-0.75], p<.0001). With 58% of events, OS for the Bev+Pem arm was also improved both from induction (19.8 v 15.9 m, HR 0.88 [0.64-1.22], p=.32) and randomization (17.1 v 13.2 m, HR 0.87 [0.63-1.21], p=.29). The PFS and OS improvements were comparable across age, PS, smoking status, and response to induction (SD vPR/CR) subgroups. No new safety signal was observed during this updated analysis. Conclusions: Continuation maintenance with Bev+Pem in an unselected population of nsNSCLC pts who had achieved disease control after induction was associated with an increase by almost 4 months in OS benefit over standard Bev alone. Clinical trial information: NCT00961415.
Collapse
Affiliation(s)
| | | | - Vera A. Gorbunova
- N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
| | | | | | | | | | - Joo-Hang Kim
- Department of Internal Medicine (Medical Oncology), Yonsei Cancer Research Institute, Yonsei Cancer Center, Seoul, South Korea
| | - Myung-Ju Ahn
- Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - Martin Reck
- Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Grosshansdorf, Germany
| | - Antonio Pazzola
- Medical Oncology - Ospedale Civile SS. Annunziata, Sassari, Italy
| | - Heung Tae Kim
- Center for Lung Cancer, National Cancer Center, Goyang, South Korea
| | | | | | | | | | - Fabrice Barlesi
- Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France
| |
Collapse
|